Shareholders IMCD N.V. adopt all resolutions at AGM
14 mai 2024 11h00 HE
|
IMCD N.V.
ROTTERDAM, The Netherlands (14 May 2024, 17:00 hrs CEST) – IMCD N.V. ("IMCD" or "Company"), a global leading distribution partner, formulator of speciality chemicals and ingredients, announces that...
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
09 mai 2024 07h45 HE
|
Virios Therapeutics
- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call...
ChainGPT Pad launches Engines of Fury, bringing enhanced Web3 gaming experiences to mainstream players
08 mai 2024 10h30 HE
|
ChainGPT
Dover, DE, May 08, 2024 (GLOBE NEWSWIRE) -- ChainGPT, the AI-powered Web3 infrastructure providing a diverse suite of tools and services, will exclusively launch the IDO of its latest launchpad...
Immunocore reports first quarter financial results and provides a business update
08 mai 2024 07h00 HE
|
Immunocore Holdings plc
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7...
Immuron Limited to Present at the Emerging Growth Conference
07 mai 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, May 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite individual...
Immuron Director Resignation
03 mai 2024 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen...
Galapagos rapporteert financiële resultaten voor het eerste kwartaal 2024
02 mai 2024 16h01 HE
|
Galapagos NV
Vooruitgang met potentiële best-in-class R&D pijplijn van celtherapie en kleine moleculen, met vier klinische assets en >15 onderzoeksprogramma's in oncologie en immunologie Overeenkomsten...
Galapagos reports first quarter 2024 financial results
02 mai 2024 16h01 HE
|
Galapagos NV
Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with...
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
02 mai 2024 09h15 HE
|
Virios Therapeutics
ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
IMCD reports EBITA of EUR 127 million in the first three months of 2024
26 avr. 2024 01h00 HE
|
IMCD N.V.
Rotterdam, The Netherlands (26 April 2024) - IMCD N.V. (“IMCD” or “Company”), a global leading distribution partner, and formulator of speciality chemicals and ingredients, today announces its first...